• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

cancer immunotherapy (immuno-oncology, I-O)

	Next higher product group	cancer drug
	Status	2012-10-06

Record changed: 2020-01-02

Advertisement

More documents for cancer immunotherapy (immuno-oncology, I-O)

• [1] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
• [2] Grey Wolf Therapeutics Ltd.. (1/9/20). "Press Release: Grey Wolf Completes £2.5 Million Series A2 Financing for Development of Therapies Targeting ERAP2". Oxford....
• [3] Zelluna Immunotherapy AS. (12/19/19). "Press Release: Zelluna Immunotherapy Appoints Namir Hassan as Chief Executive Officer". Oslo....
• [4] Bone Therapeutics S.A.. (12/19/19). "Press Release: Bone Therapeutics Announces the Appointment of Dr. Miguel Forte as CEO to Lead the Company into the Next Phase of Development". Gosselies....
• [5] Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO"....
• [6] ImmunOs Therapeutics AG. (12/10/19). "Press Release: ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer into Human Trials". Schlieren....
• [7] Mologen AG. (12/3/19). "Press Release: Insolvency Filing [Not for publication or distribution in or into US, AU, CA or JP or any jurisdiction in which unlawful]". Berlin....
• [8] Oncopeptides AB. (12/2/19). "Press Release: Oncopeptides Appoints Joseph Horvat as President North America". Stockholm....
• [9] Zelluna Immunotherapy AS. (11/19/19). "Press Release: Zelluna Immunotherapy and Glycostem Therapeutics Announce Partnership to Develop Allogeneic TCR-NK Therapies". Oslo & Oss....
• [10] Zelluna Immunotherapy AS. (11/4/19). "Press Release: Zelluna Immunotherapy Appoints Dr Bent Jakobsen, a Pioneer of TCR Therapeutics, to the Board of Directors". Oslo....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.